NVS | Novartis AG

Index- P/E31.06 EPS (ttm)3.25 Insider Own9.30% Shs Outstand2.11B Perf Week2.04%
Market Cap224.77B Forward P/E13.81 EPS next Y7.31 Insider Trans0.00% Shs Float2.10B Perf Month-2.61%
Income7.03B PEG3.94 EPS next Q1.66 Inst Own8.50% Short Float / Ratio0.20% / 1.91 Perf Quarter25.11%
Sales52.14B P/S4.31 EPS this Y-70.20% Inst Trans-8.97% Short Interest4.28M Perf Half Y10.03%
Book/sh24.67 P/B4.09 EPS next Y8.00% ROA6.00% Target Price110.75 Perf Year15.55%
Cash/sh5.51 P/C18.33 EPS next 5Y7.88% ROE12.00% 52W Range74.09 - 105.56 Perf YTD11.25%
Dividend3.50 P/FCF37.42 EPS past 5Y0.00% ROI8.90% 52W High-4.39% Beta0.54
Dividend %3.47% Quick Ratio0.80 Sales past 5Y3.60% Gross Margin71.10% 52W Low36.23% ATR1.41
Employees103000 Current Ratio1.10 Sales Q/Q3.10% Oper. Margin17.60% RSI (14)56.40 Volatility1.33% 1.10%
OptionableYes Debt/Eq0.56 EPS Q/Q8.90% Profit Margin13.50% Rel Volume1.42 Prev Close100.65
ShortableYes LT Debt/Eq0.42 EarningsApr 25 BMO Payout101.70% Avg Volume2.24M Price100.93
Recom2.20 SMA201.00% SMA501.51% SMA20014.32% Volume3,167,371 Change0.28%
Date Action Analyst Rating Change Price Target Change
Apr-26-23Upgrade Deutsche Bank Hold → Buy
Mar-27-23Upgrade Deutsche Bank Sell → Hold
Jan-26-23Downgrade Citigroup Buy → Neutral
Dec-05-22Upgrade Stifel Hold → Buy
Sep-15-22Downgrade Credit Suisse Neutral → Underperform
Sep-14-22Downgrade Berenberg Buy → Hold
May-09-22Downgrade Wolfe Research Outperform → Peer Perform
Jan-10-22Resumed Citigroup Buy
Dec-14-21Downgrade Redburn Buy → Neutral
Dec-06-21Downgrade Exane BNP Paribas Outperform → Neutral
Jun-09-23 02:10PM
01:37PM
10:52AM
08:41AM
Jun-08-23 01:03PM
09:57AM Loading…
09:57AM
08:28AM
07:00AM
03:29AM
03:03AM
01:41AM
01:15AM
Jun-07-23 11:33PM
03:05PM
02:42PM
02:01PM Loading…
02:01PM
12:46PM
07:32AM
Jun-06-23 10:58AM
10:42AM
Jun-05-23 02:52PM
11:49AM
11:45AM
11:40AM
10:24AM
Jun-02-23 12:39PM
10:33AM
09:55AM
08:06AM
08:00AM
08:00AM Loading…
08:00AM
07:12AM
Jun-01-23 12:46PM
10:40AM
04:57AM
01:15AM
May-31-23 12:09PM
12:02PM
09:42AM
May-30-23 11:14AM
May-29-23 09:40AM
May-26-23 12:33PM
12:32PM
May-25-23 05:46PM
10:15AM
01:15AM
May-24-23 03:19PM
05:00AM
May-23-23 01:29PM
08:07AM
May-22-23 12:23PM
May-19-23 12:21PM
12:04PM
11:45AM
10:24AM
May-18-23 07:00AM
May-17-23 12:38PM
11:14AM
11:13AM
May-15-23 10:35AM
01:15AM
May-11-23 12:54PM
12:15PM
May-10-23 03:41PM
12:00PM
09:40AM
May-09-23 04:09PM
03:00PM
11:28AM
10:00AM
09:42AM
07:04AM
May-08-23 08:15AM
May-05-23 12:35PM
12:00PM
May-04-23 01:15AM
May-03-23 11:45AM
11:00AM
May-02-23 03:53PM
03:49PM
01:03AM
Apr-30-23 11:00PM
Apr-29-23 09:53PM
Apr-28-23 12:47PM
12:23AM
Apr-27-23 10:07AM
Apr-26-23 03:25PM
01:57PM
12:42PM
11:21AM
11:03AM
10:21AM
05:30AM
Apr-25-23 04:02PM
01:10PM
09:44AM
09:30AM
09:11AM
08:29AM
01:11AM
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.